Cargando…
Real-world Treatment Patterns and Reasons for Therapy Selection in Patients with Advanced Hepatocellular Carcinoma in US Oncology Practices
BACKGROUND: The treatment landscape for advanced hepatocellular carcinoma (aHCC) is rapidly expanding beyond tyrosine kinase inhibitors (TKIs) in the first-line (1L) setting, with multiple TKIs and immune-checkpoint inhibitors (ICIs) now being evaluated in combination. Real-world evidence describing...
Autores principales: | Klink, Andrew J, Marshall, Landon Z, Aly, Abdalla, Seal, Brian, Healey, Marcus J, Feinberg, Bruce |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8914483/ https://www.ncbi.nlm.nih.gov/pubmed/35274709 http://dx.doi.org/10.1093/oncolo/oyab059 |
Ejemplares similares
-
Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma
por: Sanoff, Hanna K., et al.
Publicado: (2016) -
New concepts in the treatment of hepatocellular carcinoma
por: Sidali, Sabrina, et al.
Publicado: (2022) -
Textbook oncologic outcomes and regionalization among patients undergoing hepatic resection for intrahepatic cholangiocarcinoma
por: Munir, Muhammad M., et al.
Publicado: (2022) -
High pretreatment static and dynamic alpha‐fetoprotein values predict reduced overall survival in hepatocellular carcinoma
por: Czauderna, Carolin, et al.
Publicado: (2021) -
Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise
por: Saha, Supriya K., et al.
Publicado: (2016)